| Product Name | ADMA ELISA kit (General species) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Asymmetrical Dimethylarginine (ADMA). No significant cross-reactivity or interference between Asymmetrical Dimethylarginine (ADMA) and analogues was observed. |
| Synonyms | N,N-Dimethylarginine; NG,NG-Dimethylarginine dihydrochloride; Asymmetric Dimethylarginine |
| Method | Competitive |
| Detection Range | 12.35-1,000ng/mL |
| Sensitivity | 4.99ng/mL |
| Target | ADMA |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Asymmetrical Dimethylarginine (ADMA). No significant cross-reactivity or interference between Asymmetrical Dimethylarginine (ADMA) and analogues was observed. |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix.Incubate 1 hour at 37℃; 3.Aspirate and wash 3 times; 4.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 5.Aspirate and wash 5 times; 6.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 7.Add 50uL Stop Solution.Read at 450 nm immediately. |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Interactions among Vascular-Tone Modulators Contribute to High Altitude Pulmonary Edema and Augmented Vasoreactivity in Highlanders;Effect of CCL5 on dimethylarginine dimethylaminohydrolase-1 production in vascular smooth muscle cells from spontaneously hypertensive rats.;Effect of 18β-glycyrrhetinic acid on cerebral vasospasm caused by asymmetric dimethylarginine after experimental subarachnoid hemorrhage in rats.;Correlation research on ADMA plasma levels and left ventricular function of peritoneal dialysis patients;Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD;Dimethylarginine dimethylaminohydrolase-1 mediates inhibitory effect of interleukin-10 on angiotensin II-induced hypertensive effects in vascular smooth muscle cells of spontaneously hypertensive rats;Effect of 18β-glycyrrhetinic acid on cerebral vasospasm caused by asymmetric dimethylarginine after experimental subarachnoid hemorrhage in rats;Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study;Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease.;Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute toendothelial dysfunction related to insulin resistance in rats and morbidly obese humans.;Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).;A Novel Role of Irbesartan in Gastroprotection against Indomethacin-Induced Gastric Injury in Rats: Targeting DDAH/ADMA and EGFR/ERK Signaling;Multivessel analysis of progressive vascular aging in the rat: Asynchronous vulnerability among vascular territories;Arginine bioavailability and endothelin-1 system in the regulation of vascular function of umbilical vein endothelial cells from intrauterine growth restricted newborns;Probucol improves erectile function via Activation of Nrf2 and coordinates the HO-1/DDAH/PPAR-γ/eNOS pathways in streptozotocin-induced diabetic rats;Demographic, clinical and lifestyle predictors for severity of erectile dysfunction and biomarkers level in Malaysian patients;Novel cellularly active inhibitor regresses DDAH1 induced prostate tumor growth by restraining tumor angiogenesis through targeting DDAH1/ADMA/NOS pathway;The Role of Reactive Oxygen Species and Nitric Oxide in the Inhibition of Trichophyton rubrum Growth by HaCaT Cells;Blueberry anthocyanin‑enriched extract ameliorates transverse aortic constriction‑induced myocardial dysfunction via the DDAH1/ADMA/NO signaling pathway in …;Effect of a Supervised Peridialytic Exercise Program on Serum Asymmetric Dimethylarginine in Maintenance Hemodialysis Patients;The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial;Levels of endothelial substances in patients with newly identified hypertension compared with healthy controls;Non-functioning adrenal incidentalomas may increase toxic metabolites;Effect of a Low Dose of Carvedilol on Cyclophosphamide-Induced Urinary Toxicity in Rats—A Comparison with Mesna;HIF-1α and Nrf2 regulates hypoxia induced overexpression of DDAH1 through promoter activation in prostate cancer; |
| Supplier | Cloud Clone |
PROTOCOLS:
CEB301Ge All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
